Integrative Care and Treatment for Cardiorenal Syndrome

Uncover the benefits of integrative care for cardiorenal syndrome in achieving optimal patient outcomes and well-being.

Abstract

Welcome to our educational post where we delve into the intricate relationship between the heart and the kidneys, a condition known as Cardiorenal Syndrome (CRS). I am Dr. Alex Jimenez, and today, we will embark on a journey to understand the modern, evidence-based understanding of this dynamic crosstalk in acute and chronic heart failure. We will explore the latest findings from leading researchers, examining the physiological mechanisms—neurohormonal activation, inflammation, renal tubular injury, and splanchnic congestion—that drive worsening cardiac and renal function. This post will detail how we assess and evaluate patients, distinguishing between acute kidney injury (AKI) and chronic kidney disease (CKD), and cover a comprehensive diagnostic and treatment plan. Furthermore, we will explain how our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, integrates medical oversight by Dr. Maria Guadalupe Cardenas, MD, with my integrative chiropractic care, functional medicine protocols, personal injury management, and rehabilitation to provide comprehensive, evidence-based treatment for our patients. You will learn why we tailor diuretic strategies, optimize guideline-directed medical therapy (GDMT), and leverage lifestyle, biomechanical, and autonomic-regulating approaches to improve outcomes.

Our Integrative Team: A Collaborative Model of Care

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, we pride ourselves on a unique, multidisciplinary approach to patient care. I, Dr. Alex Jimenez, bring my expertise as a Doctor of Chiropractic (DC), an Advanced Practice Registered Nurse (APRN) with board certification as a Family Nurse Practitioner (FNP-BC), and certifications in Functional Medicine (CFMP, IFMCP). My focus is on understanding the body as an interconnected system and utilizing non-invasive, evidence-based therapies to restore function and well-being.

Our practice is fortified by the invaluable expertise of our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). With over 40 years of profound experience as an internist, Dr. Cardenas provides the crucial medical direction and oversight typical of multidisciplinary, integrative, and injury-care clinics where an MD collaborates with a chiropractor. This collaborative model allows us to blend the best of chiropractic, functional medicine, and conventional medicine. Together, we coordinate a spectrum of services, including medical management, integrative chiropractic care, functional medicine, rehabilitation, and personal injury services to address complex cardiometabolic, musculoskeletal, and personal injury needs, ensuring our patients receive holistic and personalized treatment plans.

Cardiorenal Syndrome: The Heart–Kidney Crosstalk

When I care for patients with heart failure, the heart–kidney axis is central. The heart is not just a pump; it is an endocrine organ producing atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP/NT-proBNP), and C-type natriuretic peptide (CNP). The kidneys—and the adrenal system—produce renin, angiotensin I/II, and aldosterone (via the RAAS pathway). In health, these systems maintain balance: natriuretic peptides promote vasodilation and natriuresis (salt and water excretion), while RAAS promotes vasoconstriction and sodium/water retention.

In heart failure, decreased cardiac output and elevated filling pressures trigger chronic RAAS and sympathetic nervous system (SNS) activation. Initially compensatory, these mechanisms become maladaptive, driving fluid retention, venous congestion, and renal injury. Over time, the kidney’s endocrine power predominates. A persistently elevated NT-proBNP is not just a sign of “heart stretch”—it reflects an endocrine attempt to counter RAAS, much like a rising TSH in hypothyroidism tries to stimulate the thyroid. Clinically, I watch this tug-of-war: the kidneys tend to win unless we intervene decisively.

The Evolution of Thought: From Forward Flow to Backward Flow

To fully grasp the current approach to managing Cardiorenal Syndrome, it is helpful to look at how our understanding has evolved. A little over forty years ago, with the rise of cardiac transplantation, we gained unprecedented access to hemodynamic data through right heart catheterizations. Initially, the prevailing belief was that contractility—the heart’s pumping strength—was the most critical factor. The focus was on improving “forward flow.” High filling pressures and the resulting congestion were seen as a necessary “cost of doing business” to maintain cardiac output.

As we gathered more hemodynamic data, our focus shifted. We began to appreciate the role of systemic vascular resistance (SVR), the resistance the heart must overcome. This led to increased use of vasodilators to lower SVR, thereby reducing afterload on the heart.

The Underappreciated Hero: The Right Ventricle

For many years, the right ventricle (RV) was overlooked, often seen as a passive conduit. All attention was on the left ventricle (LV), the “beast” that pumps blood to the body. However, we now recognize the profound importance of the right ventricle. The RV is our priming pump, managing venous return and determining how much blood gets to the LV. When the RV struggles, it leads to a pressure backup throughout the venous system. This is where the concept of “backward flow” failure becomes critical. The rising venous pressure within the abdominal organs—the portal vein, the splenic vein, and crucially, the renal vein—is the real culprit behind much of the organ dysfunction in advanced heart failure.

Abdominal and Splanchnic Congestion: The Hidden Reservoir

My clinical observations have shown that fluid does not just accumulate in the legs or lungs; it begins to pack itself into the abdominal cavity, a process known as visceral or splanchnic congestion. This is the vascular bed of the liver, spleen, omentum, and intestines.

• The liver and spleen become enlarged (splenomegaly).
• Fluid builds up around the intestines and within the abdominal wall muscles, causing abdominal wall edema.
• This is not the same as ascites (free fluid in the peritoneal cavity) but a deep, organ-level congestion.

When we perform echocardiograms, we often see the inferior vena cava (IVC) is “plump” and does not collapse properly during inspiration—a clear sign of high venous pressure. This abdominal congestion elevates intra-abdominal pressure, impairs renal venous outflow, reduces effective renal perfusion, and worsens diuretic responsiveness. When patients report bloating, early satiety, or right upper quadrant discomfort, I suspect splanchnic pooling. This aligns with current research recognizing the critical role of venous congestion—not just low perfusion—in cardiorenal deterioration (Damman et al., 2014; Mullens et al., 2020).

The Kidney Under Pressure: Understanding Veno-Renal Dynamics

The kidneys operate on a pressure gradient. Think of the glomerulus as a filter where arterial blood enters under high pressure and exits into the low-pressure venous system. This wide pressure gradient is essential for efficient filtration. When venous pressure rises due to systemic congestion, this gradient narrows, filtration becomes less effective, and the kidneys become “congested.” This has led to a paradigm shift from a “pre-renal” view (blaming low blood flow to the kidneys) to a more nuanced “veno-renal” understanding. We now know that it is equally important, if not more so, to decongest the kidneys by lowering venous pressure.

Initial Diagnostic Workup: Uncovering the Root Cause

When a patient presents with shortness of breath (dyspnea), a comprehensive diagnostic panel is essential.

Assessing Kidney Function: Baseline is Key

One of the first and most critical steps is to determine the patient’s baseline renal function. A patient may arrive at the hospital with a creatinine of 1.9 mg/dL, suggesting an Acute Kidney Injury (AKI). However, their history might reveal their creatinine has been stable at that level for months. This distinction helps us differentiate between true AKI, AKI on Chronic Kidney Disease (CKD), and their stable, chronic state, and helps set realistic treatment goals.

While creatinine is common, I increasingly rely on the Glomerular Filtration Rate (GFR), which provides a more accurate measure of kidney function and is crucial for medication dosing. Modern therapies like SGLT2 inhibitors have specific GFR thresholds for safe initiation. The GFR also helps us stage CKD from Stage 1 (GFR > 90) to Stage 5 (GFR < 15), at which point dialysis discussions begin.

Essential Laboratory Tests

• Complete Blood Count (CBC): This helps rule out other causes of dyspnea, such as anemia, which can mimic heart failure symptoms. I have seen cases where severe dyspnea was not from worsening heart failure but from a critically low hemoglobin of 5 g/dL. Correcting the anemia can lead to dramatic improvement (Anker et al., 2018).
• Comprehensive Metabolic Panel (CMP): I prefer a CMP because it includes liver function tests. The liver and kidneys are “ide or die friends”; when one struggles, the other often follows. Liver congestion from heart failure can elevate liver enzymes, which can provide crucial context.
• BNP or Pro-BNP: These key biomarkers indicate heart stress and strain.
• Lactate: Elevated lactate is a marker of poor perfusion. In heart failure, it helps me risk-stratify patients and suggests malperfusion, meaning I need to be more aggressive with treatment.
• Troponin: This is used to assess for acute myocardial injury, such as a heart attack.
• Urinalysis and Urine Microalbumin: I look for proteinuria (protein in the urine). Gross proteinuria might suggest a disease like nephrotic syndrome, which can cause severe swelling (anasarca) mistaken for heart failure.

Imaging and Other Diagnostic Tools

• Echocardiogram: This ultrasound of the heart is vital for assessing its structure and ejection fraction. My general rule is to order a new echo if the patient has not had one in the last six months.
• Renal Ultrasound: This is crucial to rule out a post-obstructive process, such as hydronephrosis (swelling of the kidneys due to urine backup).
• 12-Lead EKG: An electrocardiogram helps me look for signs of ischemia or arrhythmias, such as atrial fibrillation (A-Fib).

The Pertinent Physical Assessment

I rely on the New York Heart Association (NYHA) functional classification to quantify the impact of heart failure on a patient’s daily life, from Class I (no limitation) to Class IV (symptoms at rest). Key signs of congestion include:

• Orthopnea: Shortness of breath when lying flat. I often ask, “How many pillows do you sleep on?”
• Paroxysmal Nocturnal Dyspnea (PND): Waking up suddenly at night feeling breathless, often described as a “feeling of panic.”
• Bendopnea: A specific sign where a patient becomes short of breath from bending over to tie their shoes.
• Dyspnea on Exertion (DOE): I ask about specific functional activities, such as “Can you push a vacuum cleaner?”
• Other Signs: Weight gain, early satiety, abdominal bloating, and peripheral edema.

Phenotypes of Cardiorenal Syndrome

To tailor treatment, we identify the CRS phenotype:

• Type 1 (Acute Cardiorenal): Acute heart failure leads to AKI.
• Type 2 (Chronic Cardiorenal): Chronic heart failure causes progressive CKD.
• Type 3 (Acute Renocardiac): AKI causes acute heart failure.
• Type 4 (Chronic Renocardiac): CKD leads to cardiac dysfunction.
• Type 5 (Secondary): A systemic condition (e.g., lupus, sepsis) causes simultaneous heart and kidney dysfunction.

Optimizing Diuretic Therapy for Decongestion

When a patient is volume overloaded, diuretic therapy is a cornerstone. To optimize outcomes, I tailor the choice and dose to the site of action in the nephron.

Loop Diuretics: Choosing the Right Agent and Dose

The three agents I preferentially use are furosemide, torsemide, and bumetanide.

• Potency and Equivalence (oral): 40 mg furosemide ≈ 20 mg torsemide ≈ 1 mg bumetanide.
• Bioavailability: Oral furosemide has highly variable bioavailability (10-100%), making it unpredictable. Torsemide and bumetanide offer 80-100% bioavailability and more consistent effects. Because of this, I rarely use oral furosemide and favor torsemide or bumetanide for outpatient control.
• Dosing Rhythm: To minimize nocturia and fall risk, I time doses early morning and mid-afternoon.

A mild rise in creatinine after starting loop diuretics is often RAAS-mediated rather than AKI. I do not reflexively stop them unless there are signs of true hypoperfusion. When the diuretic ceiling is reached, I add a thiazide-type diuretic (e.g., metolazone) to achieve sequential nephron blockade rather than escalating loop diuretic doses.

Guideline-Directed Medical Therapy and Advanced Support

Improving cardiac performance unloads the venous system and benefits renal perfusion.

• Key Therapies: ARNI (sacubitril/valsartan), ACE inhibitors/ARBs, MRAs (mineralocorticoid receptor antagonists), and SGLT2 inhibitors are foundational. Dr. Cardenas oversees selection and safety, ensuring we balance benefits with renal function and hyperkalemia risks.
• SGLT2 inhibitors such as dapagliflozin and empagliflozin are game-changers. They can be initiated at an eGFR ≥ 20 mL/min/1.73 m² and confer cardio-renal protection even without diabetes (McMurray et al., 2019; Heerspink et al., 2020). They promote modest natriuresis and improve tubuloglomerular feedback.
• Inotrope Support: For patients with refractory low urine output, temporary inotropes like dobutamine or milrinone can improve cardiac output and renal perfusion.
• Ultrafiltration and Mechanical Support: For extreme fluid overload, we collaborate with nephrology for ultrafiltration. In severe cases, temporary mechanical circulatory support (Impella, Protek Duo, ECMO) can be lifesaving.

Beating the Odds: “Conquering Congestive Heart Failure”- Video

Integrative Chiropractic Care in Cardiorenal Management

Patients often ask how chiropractic integrates with heart and kidney care. Our approach is evidence-guided and coordinated with medical oversight. The nervous system, housed within the spine, is the master controller of every organ. Spinal misalignments, or subluxations, can interfere with the autonomic nervous system, disrupting signals that regulate heart rate, blood pressure, and kidney function.

• Autonomic Regulation: Gentle, low-force chiropractic techniques and targeted myofascial work reduce sympathetic overdrive and improve parasympathetic tone. Because SNS overactivation fuels inflammation and RAAS, calming the autonomic nervous system supports hemodynamic stability.
• Thoracic Mobility and Respiratory Mechanics: Improving rib cage and thoracic spine motion enhances ventilatory efficiency, reduces dyspnea, and promotes venous return through better diaphragmatic excursion. This “respiratory pump” is a major driver of venous and lymphatic return.
• Postural and Biomechanical Optimization: Correcting kyphosis and forward head posture can lower intra-abdominal pressure, potentially diminishing venous stasis in the splanchnic bed.
• Pain Reduction and Mobility: Reduced pain decreases catecholamine release and afterload, supporting cardiovascular efficiency. Improved mobility encourages graded activity, enhancing skeletal muscle pump function.

I have observed in clinical practice that patients who adopt optimized thoracic and diaphragmatic mechanics, alongside medical decongestion, often report faster relief of abdominal bloating and orthopnea. You can explore additional clinical observations at my sciatica resource and professional page:

• https://sciatica.clinic/
• https://www.linkedin.com/in/dralexjimenez/

Functional Medicine and Rehabilitation: Addressing Root Drivers

We combine functional medicine with rehabilitation to support cardio-renal physiology:

• Nutrition: Personalized sodium targets, adequate protein, and cautious potassium and magnesium
• Glycemic Control: Addressing insulin resistance, which worsens RAAS signaling.
• Sleep and Breathing: Treating sleep apnea to reduce nocturnal SNS surges.
• Graded Activity: Cardiorespiratory-friendly rehabilitation boosts the skeletal muscle pump and lowers venous congestion.

Putting It All Together: A Patient-Centered Plan

This synergy of medical direction from Dr. Cardenas, integrative chiropractic care from me, and functional medicine and rehabilitation targets the physiological drivers—congestion, RAAS/SNS overactivation, inflammation, and mechanical inefficiencies—to achieve more durable improvement. Patients can expect a clear plan to relieve congestion, close monitoring of kidney function, hands-on care to improve breathing mechanics, and practical coaching aligned with their medical therapy. By combining precise pharmacology with guideline-supported therapies and an integrative framework, we can restore hemodynamic balance and protect renal function to improve quality of life.

References

• Anker, S. D., Kirwan, B. A., van Veldhuisen, D. J., Filippatos, G., Comin-Colet, J., Cleland, J. G. F., … & FAIR-HF Trial Investigators. (2018). Effects of ferric carboxymaltose on hospitalizations and mortality in iron-deficient patients with heart failure and reduced ejection fraction: A meta-analysis. European Journal of Heart Failure, 20(1), 125-133.
• Centers for Disease Control and Prevention. (2023). Chronic Kidney Disease in the United States, 2023. U.S. Department of Health and Human Services.
• Costanzo, M. R., Guglin, M. E., Saltzberg, M. T., et al. (2007). Ultrafiltration versus intravenous diuretics for patients with acutely decompensated heart failure. New England Journal of Medicine.
• Cuffe, M. S., Califf, R. M., Adams, K. F., Jr, et al. (2002). Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. Circulation.
• Damman, K., Van Deursen, V. M., Navis, G., et al. (2014). Renal impairment, WRF, and congestion in heart failure. European Heart Journal.
• Felker, G. M., Lee, K. L., Bull, D. A., et al. (2011). Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine.
• Heerspink, H. J. L., Stefansson, B. V., Correa-Rotter, R., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine.
• McKeown, E., & Leston, A. (2021). An overview of the treatment of varicose veins. Journal of Vascular Nursing, 39(1), 33-39.
• McMurray, J. J. V., Packer, M., Desai, A. S., et al. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine.
• Miyazaki, H., Arita, T., Itoh, K., et al. (2012). Clinical pharmacology of torsemide, a new loop diuretic. Circulation.
• Mullens, W., Damman, K., Harjola, V.-P., et al. (2020). The use of diuretics in heart failure with congestion: A position statement. European Journal of Heart Failure.
• Pitt, B., Zannad, F., Remme, W. J., et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine.
• Wiviott, S. D., Raz, I., Bonaca, M. P., et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine.

SEO Tags: cardiorenal syndrome, heart failure, kidney disease, RAAS, venous congestion, diuretic therapy, SGLT2 inhibitors, ARNI, integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas MD, El Paso Injury Medical Clinic, El Paso Chiropractor, splanchnic congestion, autonomic nervous system, rehabilitation, personal injury care, NYHA Classification, GFR, creatinine, AKI, CKD, diuretic resistance, torsemide vs furosemide, mechanical circulatory support Impella